- OptiBiotix Health
- 01 April 2026 12:14:41
Source: Sharecast
The AIM-traded life sciences group said revenue for the year ended 31 December rose 30% to £1.13m, while sales orders increased 33% to £1.34m, including £212,000 carried forward into 2026.
Gross profit climbed 82% to £603,000, with gross margin improving to 53% from 38%, as operating costs remained stable at £2.6m.
The company ended the year with cash of £1.03m and holdings in ProBiotix Health and SkinBioTherapeutics with a combined market value of £6.45m.
It also highlighted continued commercial progress, including the launch of SlimBiome in Hydroxycut, a major US weight-loss supplement brand, and new distribution agreements and product launches across Asia.
Post-period, OptiBiotix reported a strong start to 2026, with more than £800,000 of orders secured in January for delivery during the year, alongside a 24 metric tonne SlimBiome order from Meelung Trading in Taiwan.
The company said that excluded additional e-commerce and subsequent orders.
It said it was now shifting strategy towards higher-growth, more sustainable operations, targeting significant cost reductions and margin improvements.
The firm said marketing and selling costs were reduced by 78% in early 2026, with further reductions in research and development and intellectual property costs expected to deliver annual savings of £500,000 to £600,000.
Improvements in production processes are also expected to reduce the cost of manufacturing SlimBiome by up to 48%, supporting higher margins.
OptiBiotix added that it was restructuring its business into distinct units, each tasked with achieving profitability by the end of 2026, as it looked to better allocate capital and drive efficiency.
“The company has made strong financial progress in 2025 with growing sales, higher margins, increased gross profit, holdings valued at £6.45m, and a record start to 2026 sales orders.”
He added that the business is now focused on “achieving commercial sustainability by accelerating its activities to reduce costs and improve margins whilst continuing to grow its top line and commercialise its second generation products”.
O’Hara said that as cost reductions took full effect and further initiatives were implemented, “we move closer to our aim of achieving profitability across all parts of the business.”
At 1117 BST, shares in OptiBiotix Health were up 6.12% at 5.2p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate